INSP · Inspire Medical Systems, Inc.

Generated second quarter revenue of $200.6 million Second quarter diluted EPS of $0.01; adjusted diluted EPS of $0.14 Second quarter operating cash flow of $23.2 million Announced strategic growth plan designed to unlock and redeploy $30 million for growth initiatives MINNEAPOLIS, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2026. “Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems. “We are also announcing a strategic growth plan designed to generate approximately $30 million of annualized growth investment capacity, which we intend to redeploy into targeted growth initiatives. We believe these actions will strengthen our operating foundation, sharpen our focus on the highest-return opportunities, and position Inspire for sustainable growth and long-term value creation.” Second Quarter 2026 Financial Results ( Second Quarter 2026 compared to Second Quarter 2025 ) Revenue decreased 7.6% to $200.6 million, primarily driven by a decline in U.S. revenue, partially offset by growth in International revenue. The U.S. decline was driven primarily by the impacts of evolving coding and reimbursement environment. Gross margin increased 150 bps to 85.5%, primarily due to increased sales mix of the Inspire V system, which has a higher gross margin than the Inspire IV system. Operating expenses decreased $13.8 million, or 7.4%, to $172.0 million, primarily driven by lower stock-based compensation costs due to accelerated stock-based compensation expenses recognized in the prior year period as well as lower marketing expenses. Operating earnings increased $2.8 million to an operating loss of $0.5 million, and operating margin of (0.3)%. Adjusted operating income was $3.2 million, and adjusted operating margin was 1.6%. Interest and dividend income, net decreased by $0.7 million, primarily due to lower average interest rates and lower average cash, cash equivalents, and investment balances. Other expense, net decreased by $3.4 million, primarily due to a $4.0 million impairment charge recognized in the prior year period, partially offset by a decrease in interest and dividend income in the current period due to lower average interest rates and lower average cash, cash equivalents, and investment balances in the current period. The effective tax rate was 89.9% compared to (54.0)%. The increase in the effective tax rate was primarily driven by tax shortfall related to stock-based compensation. For the three months ended June 30, 2025, the Company maintained a full valuation allowance against federal and state deferred tax assets, which was subsequently released at December 31, 2025. Net earnings was $0.3 million and adjusted net earnings was $4.0 million. Diluted EPS was $0.01 and adjusted diluted EPS was $0.14. Financial Condition Net cash provided by operating activities for the three months ended June 30, 2026 was $23.2 million, compared to $2.7 million in the prior year period. The change was primarily driven by improved working capital, primarily in receivables and inventories. As of June 30, 2026, cash, cash equivalents, and investments increased $10.6 million to $415.2 million as compared to December 31, 2025. Full Year 2026 Guidance The Company is raising its previously announced revenue outlook to be in the range of $835 million to $875 million. Additionally, the Company now expects annual adjusted operating margin to be in the range of 4% to 6%, diluted EPS to be in the range of $(0.42) to $

Board appointment adds proven medical device leadership MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of seasoned medical device executive Michael H. Carrel to its Board of Directors effective July 20. “We are pleased to welcome Mr. Carrel to our Board of Directors,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “Mike brings extensive executive leadership, board and medical device experience, including a strong track record of developing and commercializing minimally invasive therapies, and we look forward to his guidance as we continue advancing Inspire therapy for the many patients affected by OSA.” Mr. Carrel has served as President, Chief Executive Officer, and a director of AtriCure, Inc. (NASDAQ: ATRC), an innovative cardiac device company, since November 2012. Under Mr. Carrel’s leadership, AtriCure has advanced a robust pipeline of novel products for the treatment of atrial fibrillation, left atrial appendage management and pain management. During his tenure, AtriCure has grown from $82 million in revenue in 2013 to $535 million in 2025 while helping more than one million patients. Previously, Mr. Carrel served as Chairman of the Board of Directors of Axonics, Inc. from 2019 through 2024, until its sale to Boston Scientific Corporation. Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School of the University of Pennsylvania. “I am excited to join Inspire at this important stage in the Company’s growth,” said Mr. Carrel. “With the recent launch of the fifth-generation Inspire device, a compelling product pipeline and a growing body of evidence demonstrating the long-term benefits of Inspire therapy, particularly in cardiovascular health, I believe the Company is well positioned to continue expanding access to care for patients with OSA.” About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA-, EU MDR- and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com . Investor and Media Contact Ezgi Yagci Vice President, Investor Relations [email protected] 617-549-2443 Source: Inspire Medical Systems

MINNEAPOLIS, July 22, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the retirement of Casey M. Tansey from the Inspire Board after more than eighteen years of service, effective July 30. “We are thankful for the many contributions Mr. Tansey has made to our Board of Directors over the past eighteen years,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “As one of the first venture investors to recognize the potential impact of Inspire therapy for patients with OSA, Mr. Tansey has provided valuable mentorship, leadership, and perspective throughout the Company’s founding, initial public offering and subsequent growth. We are grateful for his long-standing commitment and wish Mr. Tansey the very best in the future.” Mr. Tansey represented U.S. Venture Partners, led Inspire’s Series A financing in November 2007 and has served on the Inspire Board of Directors since that time. The Company expects to announce the appointment of a new Director to replace Mr. Tansey in the near future. About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA-, EU MDR- and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com . Investor and Media Contact Ezgi Yagci Vice President, Investor Relations [email protected] 617-549-2443 Source: Inspire Medical Systems

MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- This press release corrects the earnings release date included in the earlier version issued on July 6, 2026. No other information has changed. Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, August 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2026 earnings call webcast . For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Inspire's Q2 2026 earnings call . After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks. About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com . Investor and Media Contact Ezgi Yagci Vice President, Investor Relations [email protected] 617-549-2443 Source: Inspire Medical Systems

MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, August 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2026 earnings call webcast . For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Inspire's Q2 2026 earnings call . After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks. About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com . Investor and Media Contact Ezgi Yagci Vice President, Investor Relations [email protected] 617-549-2443 Source: Inspire Medical Systems

Highlights New Clinical Data, Technology Advancements, and Cardiovascular Outcomes Research MINNEAPOLIS, June 16, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced its participation in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14–17 in Baltimore, Maryland. SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS). Advancing Innovation and Clinical Evidence “We are pleased to return to SLEEP and showcase the continued evolution of the Inspire platform, including the Inspire V system, alongside compelling new clinical data demonstrating real-world effectiveness,” said Tim Herbert, Chairman and Chief Executive Officer. “Our long-standing partnership with SLEEP reflects our commitment to advancing physician education and improving outcomes for patients with OSA worldwide.” At Booth #525, attendees can explore: The Inspire V system and recent technology advancements Clinical evidence supporting closed-loop therapy detailing respiratory sensing and inspiratory overlap The Inspire SleepSync™ remote patient management platform Resources for establishing and scaling Inspire programs New Clinical Insights: Hypoxic Burden and Cardiovascular Outcomes Multiple presentations at SLEEP 2026 will highlight the growing body of evidence supporting Inspire therapy, particularly in improving cardiovascular risk markers. Separately, Inspire will highlight additional research at its exhibit booth, including recent peer-reviewed articles on hypoxic burden and cardiovascular outcomes, which complement these presentations and are not being presented as part of the SLEEP 2026 program. The first article from Dr. Xu 1 is a secondary analysis from the STAR trial that demonstrated: Significant reductions in hypoxic burden, a key physiologic measure of oxygen desaturation linked to OSA risk Improvements in daytime sleepiness that correlate with hypoxic burden reduction, independent of AHI or arousal index changes Meaningful hypoxic burden improvements in at least 50% of AHI non-responders, supporting its role as a complementary biomarker Hypoxic burden is a measure of the total impact of oxygen desaturation events during sleep, integrating the depth, duration, and frequency of these events to quantify sleep apnea severity These findings reinforce hypoxic burden as an emerging and clinically relevant endpoint and align with a growing number of studies evaluating cardiovascular outcomes in patients treated with Inspire therapy versus Continuous Positive Airway Pressure (CPAP) and untreated populations. 1 – Xu et al, Hypoglossal Nerve Stimulation and Hypoxic Burden in Patients with Obstructive Sleep Apnea - A Secondary Analysis of the STAR Trial ; JAMA Otolaryngology Head Neck Surg. doi:10.1001/jamaoto.2026.1049 Published online May 21, 2026 The second article from Dr. Nayak <

MINNEAPOLIS, June 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on Friday, June 26, 2026. Inspire is scheduled to speak at 10:00 a.m. Eastern Time. The presentation will be accessible via a live webcast here . A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com . About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com . Investor and Media Contact Ezgi Yagci Vice President, Investor Relations [email protected] 617-549-2443 Source: Inspire Medical Systems

First quarter revenue growth of 1.6% First quarter diluted EPS of $(0.39); adjusted diluted EPS of $0.10 First quarter operating cash flow of $12.8 million MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2026. “Our first quarter results reflect revenue growth and improved adjusted operating income and cash flow,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems. “We remain focused on the factors within our control, including prioritizing revenue-generating activities and maintaining disciplined cost management, while continuing targeted investments to support long-term growth and we believe these actions position the Company well in both the near and long term.” “Despite disruption from the coding and reimbursement uncertainty that arose at the beginning of the year, as well as the implementation of the WISeR program, we continued to advance the adoption of Inspire V given its simplified procedure and advanced features. As previously discussed, the CPT code used for approximately 10,000 Inspire V cases in 2025 is no longer available for reimbursement of Medicare cases, requiring physicians, centers, and our team to navigate coding alternatives during the quarter. We are proud of the team for delivering solid results and helping physicians and customers navigate through this uncertainty.” “We are continuing to work with key stakeholders to implement solutions that will resolve the coding and reimbursement uncertainty for Inspire V,” continued Mr. Herbert. “We expect the challenges caused by this uncertainty to persist through the balance of 2026. That said, we believe that these challenges are temporary, and we expect to return to revenue growth in 2027 by leveraging the strength of the positive clinical outcomes of the Inspire V system.” First Quarter 2026 Financial Results ( First Quarter 2026 compared to First Quarter 2025 ) Revenue increased 1.6% to $204.6 million, primarily driven by increased market penetration, offset by the adverse effects of reimbursement disruption and the Wasteful and Inappropriate Service Reduction (WISeR) program. Gross margin increased 180 bps to 86.5%, primarily due to increased sales mix of the Inspire V system, which has a higher gross margin than the Inspire IV system. Operating expenses increased $5.9 million, or 3.4%, to $178.0 million, primarily driven by higher marketing expenses, legal fees and employee-related costs, partially offset by lower R&D expenses. Operating loss decreased $0.4 million to $1.1 million, and operating margin was (0.5)%. Adjusted operating income was $0.3 million, and adjusted operating margin was 0.2%. Interest and dividend income decreased by $1.3 million, primarily due to lower average interest rates and lower average cash, cash equivalents, and investment balances. The effective tax rate was 571.2% compared to 28.1%. The increase in the effective tax rate was primarily driven by shortfalls related to stock-based compensation, which were driven by a decline in our stock price at award vesting and exercise compared to grant-date fair value (tax shortfall). For the three months ended March 31, 2025, we maintained a full valuation allowance against federal and state deferred tax assets, which was subsequently released at Dec

MINNEAPOLIS, April 29, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026. Inspire is scheduled to present at 11:00 a.m. Eastern Time. The presentation will be accessible via a live webcast here . A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com . About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com . Investor and Media Contact Ezgi Yagci Vice President, Investor Relations [email protected] 617-549-2443 Source: Inspire Medical Systems

MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2026 after the close of trading on Monday, May 4. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q1 2026 earnings call webcast . For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Inspire's Q1 2026 earnings call . After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks. About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com . Investor and Media Contact Ezgi Yagci Vice President, Investor Relations [email protected] 617-549-2443 Source: Inspire Medical Systems

MINNEAPOLIS, March 03, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026. Inspire is scheduled to present at 1:30 p.m. Eastern Time. The presentation will be accessible via a live webcast here . A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com . About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com . Investor and Media Contact Ezgi Yagci Vice President, Investor Relations [email protected] 617-549-2443 Source: Inspire Medical Systems

Launch of Inspire V system complete with strong revenue and profitability performance in the fourth quarter and FDA approval for 3.0T MRI compatibility Fourth quarter revenue growth of 12% and full year revenue growth of 14% Fourth quarter net income per diluted share of $4.66; adjusted net income per diluted share of $1.65 Full year net income per diluted share of $4.89; adjusted net income per diluted share of $2.42 Operating cash flow of $52.5 million in the fourth quarter with full year operating cash flow of $117.0 million MINNEAPOLIS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2025. “We are very excited with the strong finish to 2025. The team made excellent progress with the Inspire V launch, with clinical insights from the early phase of commercial adoption continuing to validate positive patient outcomes and improvements in therapy delivery,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems. “Despite the dynamic reimbursement landscape, our strong fourth quarter execution positions us well as we enter 2026.” “In the last week, we received clarification regarding the coding that should be used for the Inspire V procedure. Currently, healthcare centers and physicians should bill the most recent healthcare policies, be it a Medicare Administrative Contractor (MACs) or a commercial payor, and based on this clarification, we believe the code will transition to CPT code 64582 for the Inspire V procedure, including the use of a -52 modifier,” continued Mr. Herbert. “While we are disappointed with this result, this clarification provides direction for us going forward, and we will work with payers, including the MACs, government agencies, commercial payers and physician societies to attempt to minimize the impact to the physician fee from this change. Additionally, we are seeking a long-term solution, namely the creation of a separate CPT code that would support appropriate reimbursement for the Inspire V procedure. We remain focused on our commitment to put the patient first and deliver strong patient outcomes. We believe we have a differentiated product, a strong team and that we can drive long-term profitable growth and shareholder value.” Fourth Quarter 2025 Financial Results (Fourth Quarter 2025 compared to Fourth Quarter 2024) Revenue increased 12% to $269.1 million primarily driven by growth at existing centers and new center additions. Gross margin increased 160 bps to 86.6% primarily due to increased sales volume as well as increased sales mix of the Inspire V system. Operating expenses increased 9%, or $15.0 million, to $186.9 million primarily driven by higher investments in patient marketing and education expenses, partially offset by lower R&D expenses. Operating income increased $14.2 million to $46.1 million, and operating margin was 17.1%. Adjusted operating income was $47.1 million, and adjusted operating margin was 17.5%. Income tax was a benefit of $85.8 million, primarily driven by the release of the valuation allowance against net deferred tax assets. Net income was $136.1 million and adjusted net income was $48.1 million. Net income per diluted share was $4.66 and adjusted net income per diluted share was

Inspire Announces Appointment of Matt Osberg as Executive Vice President and Chief Financial Officer Joining the Company in the First Quarter of 2026 MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025, and provided its initial full year 2026 revenue guidance. Further, the Company announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full Year 2025 Revenue Revenue for the fourth quarter of 2025 is anticipated to be in the range of $268.9 million to $269.1 million, an approximately 12% increase over the same quarter of 2024 Revenue for full year 2025 is anticipated to be in the range of $911.8 million to $912.0 million, an approximately 14% increase over full year 2024 Initial Full Year 2026 Revenue Guidance Revenue for full year 2026 is anticipated to be in the range of $1,003 million to $1,013 million, a 10% to 11% increase over full year 2025 “We are very pleased with our strong preliminary revenue performance in the fourth quarter as the team executed exceptionally well and finished the year with significant momentum,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “2025 was a transition year for the company with the launch of the Inspire V system, and momentum grew significantly throughout the second half of the year, and we are very proud of the strong acceptance of this fifth-generation Inspire system further evidenced by the safety and clinical evidence that was presented throughout the year.” “With the momentum we are seeing, we are pleased to reaffirm the preliminary outlook we provided on our third quarter earnings call of 10% to 11% revenue growth in 2026 as compared to 2025. We view the recent reimbursement developments as a positive step and are continuing to work with the relevant agencies to gain clarification on coding. Our outlook does not include any contribution from increased reimbursement at this time, and we will continue to provide updates, including on our upcoming earnings call,” continued Mr. Herbert. Chief Financial Officer Announcement The Company also announced the appointment of Matt Osberg as its new Executive Vice President and Chief Financial Officer. Mr. Osberg is an accomplished C-suite financial executive with over 20 years of experience in global financial leadership, corporate governance, and strategic transformation across diverse industries and geographies. Mr. Osberg was most recently Executive Vice President and Chief Financial Officer at Apogee Enterprises, Inc. in Minneapolis, MN. Previously, he was the Chief Financial Officer at Helen of Troy, Ltd in El Paso, TX, and prior to that held various finance leadership roles at Best Buy, Inc. Mr. Osberg started his career at Ernst & Young LLP. Mr. Osberg’s start date is January 19, 2026. “We are very excited to have Matt Osberg join Inspire and bring his years of public company experience to take us through our next wave of growth as we continue the adoption of Inspire therapy globally,” continued Mr. Herbert. “Finally, we wish to thank Rick Buchholz for his many years at Inspire and wish him well in his future endeavors.” Inspire previously announced its participation in the 44 th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA, including a formal company <a href="https://www.globenewswire.com/Tracker?data

MINNEAPOLIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the fourth quarter and full year 2025 after the close of trading on Wednesday, February 11. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q4 2025 earnings call webcast . For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Inspire's Q4 2025 earnings call . After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks. About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com . Investor and Media Contact Ezgi Yagci Vice President, Investor Relations [email protected] 617-549-2443 Source: Inspire Medical Systems

MINNEAPOLIS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Inspire is scheduled to present at 12:45 p.m. Eastern Time. The presentation will be accessible via a live webcast here . A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com . About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com . Investor and Media Contact Ezgi Yagci Vice President, Investor Relations [email protected] 617-549-2443 Source: Inspire Medical Systems